RESUMO
This short report summarizes the results of recent immunological studies performed at the new Sirius University of Science and Technology. The report focuses on studying the features of the immune response to vaccination and revaccination against SARS-CoV-2, as well as on a search of potential agents to prevent infection with this virus.
Assuntos
COVID-19 , Humanos , SARS-CoV-2 , Tecnologia , Vacinação , Anticorpos Antivirais , Anticorpos NeutralizantesRESUMO
SARS-CoV-2 is a new coronavirus that is the cause of COVID-19 pandemic. To enter the cell, the virus interacts via its surface S protein with angiotensin-converting enzyme 2 (ACE2), the main entry receptor on the cell membrane. Most of protective antibodies, including those induced by vaccinations, target the S protein, preventing its interaction with the ACE2 receptor. We have evaluated an alternative strategy for blocking the S-ACE2 interaction using new antipeptide antibodies to the N-terminus of the ACE2 molecule. These antibodies allow detection of human ACE2 in vitro and ex vivo.
Assuntos
Enzima de Conversão de Angiotensina 2/imunologia , COVID-19 , Pandemias , Angiotensinas/metabolismo , Humanos , Pandemias/prevenção & controle , Ligação Proteica , SARS-CoV-2 , Glicoproteína da Espícula de CoronavírusRESUMO
This short report summarizes the results of recent immunological studies performed at new Sirius University of Science and Technology. The report focuses on studying the features of the immune response to vaccination and revaccination against SARS-CoV-2, as well as on a search of potential agents to prevent infection with this virus.